Unigene Laboratories will receive $2.5 million to supply Novartis with specified quantities of a bulk peptide necessary for development of its osteoporosis treatment.
Unigene will develop a process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary.
In 2004, Novartis exclusively licensed Unigene's technology to manufacture another peptide, calcitonin, and it now runs the scaled-up process at its manufacturing facility in Kundl, Austria.